DK1326634T3 - Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber - Google Patents

Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Info

Publication number: DK1326634T3
Authority: DK; Denmark
Prior art keywords: peptide; antigen; amino acid; acid residue; vaccine composition
Prior art date: 2000-10-18

Application number

DK01980496T

Other languages

Danish (da)

English (en)

Inventor

Joerg Fritz

Frank Mattner

Michael Buschle

Wolfgang Zauner

Eszter Nagy

Original Assignee

Intercell Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2001-10-18

Publication date

2006-08-14

2001-10-18 Application filed by Intercell Ag filed Critical Intercell Ag

2006-08-14 Application granted granted Critical

2006-08-14 Publication of DK1326634T3 publication Critical patent/DK1326634T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK01980496T 2000-10-18 2001-10-18 Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber DK1326634T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT0178900A AT410635B (de)	2000-10-18	2000-10-18	Vakzin-zusammensetzung

Publications (1)

Publication Number	Publication Date
DK1326634T3 true DK1326634T3 (da)	2006-08-14

Family

ID=3688953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01980496T DK1326634T3 (da)	2000-10-18	2001-10-18	Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber

Country Status (26)

Country	Link
US (3)	US8361476B2 (fr)
EP (1)	EP1326634B1 (fr)
JP (2)	JP4227407B2 (fr)
KR (1)	KR100598302B1 (fr)
CN (1)	CN1248736C (fr)
AT (2)	AT410635B (fr)
AU (2)	AU2002212326B2 (fr)
BR (1)	BRPI0114994B8 (fr)
CA (1)	CA2426490C (fr)
CZ (1)	CZ303303B6 (fr)
DE (1)	DE60119145T2 (fr)
DK (1)	DK1326634T3 (fr)
ES (1)	ES2263668T3 (fr)
HU (1)	HU228382B1 (fr)
IL (2)	IL154605A0 (fr)
IS (1)	IS2608B (fr)
MX (1)	MXPA03002828A (fr)
NO (1)	NO330274B1 (fr)
NZ (1)	NZ524532A (fr)
PL (1)	PL209016B1 (fr)
PT (1)	PT1326634E (fr)
RU (2)	RU2328305C2 (fr)
SI (1)	SI1326634T1 (fr)
SK (1)	SK287618B6 (fr)
WO (1)	WO2002032451A1 (fr)
ZA (1)	ZA200301465B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT410635B (de) *	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
US7244438B2 (en)	2001-01-05	2007-07-17	Intercell Ag	Uses for polycationic compounds
CA2433794A1 (fr) *	2001-01-05	2002-07-11	Intercell Ag	Utilisations de composes polycationiques
AT410798B (de)	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (fr)	2001-07-26	2003-01-29	Istituto Superiore di Sanità	Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN1650012A (zh)	2002-07-24	2005-08-03	英特塞尔股份公司	来自致病病毒的备选阅读框所编码的抗原
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004024182A2 (fr)	2002-09-13	2004-03-25	Intercell Ag	Procede pour isoler des peptides du virus de l'hepatite c
CN102174533A (zh)	2002-10-15	2011-09-07	英特塞尔股份公司	编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
EP2287315A1 (fr)	2003-03-04	2011-02-23	Intercell AG	Antigènes pyogènes streptococcus
CA2519922A1 (fr) *	2003-03-24	2004-10-07	Intercell Ag	Utilisation d'alun et d'un adjuvant induisant une reponse immunitaire du type genere par une th1 pour renforcer des reponses immunitaires
DE602004029657D1 (de)	2003-03-24	2010-12-02	Intercell Ag	Verbesserte impfstoffe
JP2007523609A (ja)	2003-03-31	2007-08-23	インターツェル・アクチェンゲゼルシャフト	表皮ブドウ球菌抗原
EP1615950A2 (fr)	2003-04-15	2006-01-18	Intercell AG	Antigenes s-pneumoniae
US8076059B2 (en) *	2003-04-16	2011-12-13	Duke University	Adjuvant capable of specifically activating the adaptive immune response
CN101864431A (zh)	2003-05-07	2010-10-20	英特塞尔股份公司	无乳链球菌抗原ⅰ和ⅱ
US20080175856A1 (en)	2003-05-30	2008-07-24	Intercell Ag	Enterococcus Antigens
EP1648502B1 (fr) *	2003-07-11	2010-12-01	Intercell AG	Vaccins contre le virus de l'hepatite c
ES2297688T3 (es)	2004-03-12	2008-05-01	Intercell Ag	Procedimiento para solubizar mezclas de peptidos.
ES2556710T3 (es)	2004-09-24	2016-01-19	Novartis Ag	Proteínas capsidiales VP1 modificadas del parvovirus B19
EP1931379B1 (fr)	2005-10-07	2013-05-29	Health Protection Agency	Proteines a solubilite amelioree et methodes de production et d'utilisation desdites proteines
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007264205B2 (en)	2006-06-28	2013-04-18	Statens Serum Institut	Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
CN101490083A (zh)	2006-07-07	2009-07-22	英特塞尔股份公司	小化脓性链球菌抗原及其用途
EP2289906A1 (fr)	2006-09-15	2011-03-02	Intercell AG	Antigènes de la Borrelia
EP1923069A1 (fr)	2006-11-20	2008-05-21	Intercell AG	Peptides protecteurs contre S. pneumoniae et compositions, méthodes et utilisations associés
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2266591A3 (fr)	2007-01-12	2012-08-08	Intercell AG	Protéines protectrices de S. agalactia, combinaisons associées et procédés d'utilisation
EP2489673A3 (fr)	2007-05-02	2012-09-12	Intercell AG	Antigènes de Klebsiella
DK2158211T3 (en)	2007-05-31	2016-12-05	Medigene Ag	Mutated structural protein of a parvovirus
EP2012122A1 (fr)	2007-07-06	2009-01-07	Medigene AG	Protéines structurelles de parvovirus muté
EP2167530A2 (fr)	2007-06-18	2010-03-31	Intercell AG	Antigènes de chlamydia
EP2265634A2 (fr)	2008-03-17	2010-12-29	Intercell AG	Peptides protecteurs contre s. pneumoniae et compositions, procédés et utilisations se rapportant a ceux-ci
KR101614344B1 (ko)	2008-04-02	2016-04-21	토쿠시마 대학	합성 펩티드를 함유하는 항원약물 비이클과 이것을 사용하는 점막 백신
CN102316894A (zh)	2008-06-20	2012-01-11	惠氏有限责任公司	来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
US20100015171A1 (en) *	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
EP2424882A2 (fr)	2009-02-05	2012-03-07	Intercell AG	PEPTIDES PROTECTEURS CONTRE E. FAECALIS, PROCÉDÉS ET UTILISATIONS LIÉS À CEUX-CI& xA;
US8617574B2 (en)	2009-02-13	2013-12-31	Valneva Austria Gmbh	Nontypable Haemophilus influenzae antigens
SA110310528B1 (ar)	2009-06-22	2014-07-02	Wyeth Llc	التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
PE20110065A1 (es)	2009-06-22	2011-01-31	Wyeth Llc	Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
US8858958B2 (en)	2009-08-27	2014-10-14	Novartis Ag	Adjuvant comprising aluminum, oligonucleotide and polycation
EP2319871A1 (fr)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
KR20120089863A (ko)	2009-10-09	2012-08-14	사노피	“개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
EP2308896A1 (fr)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant
EP2536427A1 (fr)	2010-02-19	2012-12-26	Intercell AG	Nanoparticules d'ic31
WO2012020326A1 (fr)	2010-03-18	2012-02-16	Novartis Ag	Vaccins adjuvantés contre le méningocoque de sérogroupe b
PT2575870T (pt)	2010-06-04	2017-02-10	Wyeth Llc	Formulações de vacinas
HUE034544T2 (hu)	2010-08-23	2018-02-28	Wyeth Llc	Neisseria meningitidis rLP2086 antigént tartalmazó stabil készítmények
SMT201700124T1 (it)	2010-09-03	2017-05-08	Valneva Austria Gmbh	Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
WO2012031760A1 (fr)	2010-09-08	2012-03-15	Medigene Ag	Protéines structurales mutées de parvovirus comprenant des épitopes de cellules b induisant une protection croisée d'une protéine l2 du hpv ainsi que produits et procédés s'y rapportant
JP5976652B2 (ja)	2010-09-10	2016-08-24	ワイス・エルエルシー	髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
MX350170B (es)	2010-12-22	2017-08-28	Wyeth Llc	Composición inmunogénica estable de antígenos de staphylococcus aureus.
BRPI1100857A2 (pt) *	2011-03-18	2013-05-21	Alexandre Eduardo Nowill	agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it)	2011-06-28	2012-12-29	Canio Buonavoglia	Vaccino per coronavirus canino
KR101784644B1 (ko)	2012-03-09	2017-10-11	화이자 인코포레이티드	수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013169922A1 (fr) *	2012-05-08	2013-11-14	Western University Of Health Sciences	Plateformes ex vivo standardisées pour l'expansion antigène-spécifique de populations de lymphocytes t cd4+
EA039237B1 (ru) *	2012-10-29	2021-12-21	Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас	Применение маннозилированного хитозана в качестве адъюванта в составе вакцин для пероральной или мукозной доставки
MX363512B (es)	2012-12-20	2019-03-26	Pfizer	Proceso de glicoconjugacion.
EP2964665B1 (fr)	2013-03-08	2018-08-01	Pfizer Inc	Polypeptides immunogènes de fusion
US20140271723A1 (en) *	2013-03-15	2014-09-18	Saint Louis University	Adjuvant compositions and methods of using thereof
CN105492021B (zh)	2013-09-08	2018-12-04	辉瑞公司	脑膜炎奈瑟氏球菌组合物及其方法
WO2016130569A1 (fr)	2015-02-09	2016-08-18	Mj Biologics, Inc.	Composition contenant des antigènes du vdep et procédés de fabrication et d'utilisation de la composition
CN107249626A (zh)	2015-02-19	2017-10-13	辉瑞大药厂	脑膜炎奈瑟球菌组合物及其方法
JP6948951B2 (ja)	2015-05-04	2021-10-13	ファイザー・インク	Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用
CN113813231B (zh) *	2016-07-01	2022-06-21	四川大学	抗菌肽衍生物在制备核酸载体中的用途及核酸载体
US10751402B2 (en)	2016-11-09	2020-08-25	Pfizer Inc.	Immunogenic compositions and uses thereof
EP3577130A2 (fr)	2017-01-31	2019-12-11	Pfizer Inc	Compositions de neisseria meningitidis et méthodes associées
WO2018187515A1 (fr) *	2017-04-04	2018-10-11	Avidea Technologies, Inc.	Vaccins à base de peptides, procédés de fabrication et utilisations de ceux-ci pour induire une réponse immunitaire
CN107266585B (zh) *	2017-07-13	2019-08-06	陕西科技大学	一种mlh融合抗菌肽及其制备方法和应用
CA3089790A1 (fr)	2018-02-16	2019-08-22	2A Pharma Ab	Proteine structurale de parvovirus pour le traitement de maladies auto-immunes
EP3527223A1 (fr)	2018-02-16	2019-08-21	2A Pharma AB	Protéine structurelle de parvovirus muté
CN109745556A (zh) *	2019-03-01	2019-05-14	龙阔（苏州）生物工程有限公司	一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
WO2020234300A1 (fr)	2019-05-20	2020-11-26	Valneva Se	Vaccin sous-unitaire pour le traitement ou la prévention d'une infection des voies respiratoires
CN115605222A (zh)	2019-09-27	2023-01-13	辉瑞公司（Us）	脑膜炎奈瑟氏菌组合物及其方法
WO2021202456A1 (fr) *	2020-03-30	2021-10-07	The Wistar Institute Of Anatomy And Biology	Mimétiques de récepteurs solubles synthétiques et procédés d'utilisation pour le traitement de la covid-19
EP4136095A1 (fr)	2020-04-17	2023-02-22	Regents of the University of Minnesota	Domaine de liaison au récepteur de spicule du sars-cov-2 et compositions et méthodes associées
EP4203995A1 (fr)	2020-08-26	2023-07-05	Pfizer Inc.	Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
BR112023017274A2 (pt)	2021-04-09	2023-11-14	Valneva Se	Vacina contra metapneumovírus humano
WO2023083964A1 (fr)	2021-11-11	2023-05-19	2A Pharma Ab	Protéine structurale de parvovirus dirigée contre hpv bêta-et gamma
WO2024069420A2 (fr)	2022-09-29	2024-04-04	Pfizer Inc.	Compositions immunogènes comprenant un trimère de protéine f rsv

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2168582A1 (fr) *	1993-08-06	1995-02-16	John D. Fikes	Clonage et caracterisation du gene mage-1 complet
JP3442824B2 (ja) *	1993-08-30	2003-09-02	理化学研究所	抗菌性ペプチド類
JP3547504B2 (ja) *	1994-11-01	2004-07-28	独立行政法人理化学研究所	新規なポリペプチド及びその用途
EP0991767A1 (fr)	1997-06-11	2000-04-12	Institut Pasteur	Mycobacteries de recombinaison attenuees utilisables comme immunogenes ou composants vaccinaux
AU760034B2 (en)	1997-08-29	2003-05-08	Corixa Corporation	Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CU22700A1 (es) *	1997-09-29	2001-07-31	Ct Ingenieria Genetica Biotech	Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) *	2000-09-21	2002-06-13	Oleg Chertov	LL-37 is an immunostimulant
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
CA2519922A1 (fr)	2003-03-24	2004-10-07	Intercell Ag	Utilisation d'alun et d'un adjuvant induisant une reponse immunitaire du type genere par une th1 pour renforcer des reponses immunitaires
DE602004029657D1 (de) *	2003-03-24	2010-12-02	Intercell Ag	Verbesserte impfstoffe
EP1648502B1 (fr)	2003-07-11	2010-12-01	Intercell AG	Vaccins contre le virus de l'hepatite c

2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
2001
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/fr not_active Ceased
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 CA CA2426490A patent/CA2426490C/fr not_active Expired - Lifetime
- 2001-10-18 BR BR0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko not_active Expired - Lifetime
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 EP EP01980496A patent/EP1326634B1/fr not_active Expired - Lifetime
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en not_active Expired - Lifetime
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1326634B1 (fr)	2006-04-26
HUP0302117A3 (en)	2004-11-29
CN1468109A (zh)	2004-01-14
CN1248736C (zh)	2006-04-05
AU1232602A (en)	2002-04-29
BRPI0114994B1 (pt)	2017-11-07
CZ303303B6 (cs)	2012-07-25
NO20031595D0 (no)	2003-04-08
US20090123486A1 (en)	2009-05-14
CA2426490A1 (fr)	2002-04-25
IS2608B (is)	2010-04-15
CA2426490C (fr)	2012-01-31
KR100598302B1 (ko)	2006-07-07
PL362966A1 (en)	2004-11-02
ZA200301465B (en)	2004-02-24
DE60119145D1 (de)	2006-06-01
PT1326634E (pt)	2006-09-29
NO20031595L (no)	2003-06-05
AU2002212326B2 (en)	2006-01-05
BRPI0114994B8 (pt)	2021-05-25
BR0114994A (pt)	2003-09-30
US20130216583A1 (en)	2013-08-22
JP2008222721A (ja)	2008-09-25
ATA17892000A (de)	2002-11-15
US8361476B2 (en)	2013-01-29
NO330274B1 (no)	2011-03-14
DE60119145T2 (de)	2007-02-01
AT410635B (de)	2003-06-25
RU2007146372A (ru)	2009-06-20
ATE324116T1 (de)	2006-05-15
US20050063978A1 (en)	2005-03-24
IL154605A0 (en)	2003-09-17
HU228382B1 (en)	2013-03-28
KR20030043993A (ko)	2003-06-02
PL209016B1 (pl)	2011-07-29
EP1326634A1 (fr)	2003-07-16
SK287618B6 (sk)	2011-04-05
WO2002032451A1 (fr)	2002-04-25
IS6722A (is)	2003-02-20
MXPA03002828A (es)	2003-07-14
IL154605A (en)	2009-05-04
CZ20031299A3 (cs)	2003-10-15
HK1055899A1 (en)	2004-01-30
NZ524532A (en)	2004-10-29
JP4227407B2 (ja)	2009-02-18
WO2002032451A8 (fr)	2002-05-23
ES2263668T3 (es)	2006-12-16
SI1326634T1 (sl)	2006-10-31
JP2004511528A (ja)	2004-04-15
HUP0302117A2 (hu)	2003-09-29
RU2328305C2 (ru)	2008-07-10
US8900564B2 (en)	2014-12-02
SK5752003A3 (en)	2003-12-02

Publication	Publication Date	Title
DK1326634T3 (da)	2006-08-14	Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
RU2003114434A (ru)	2004-09-20	Вакцинная композиция
ATE209216T1 (de)	2001-12-15	Cyclosporin-derivate mit anti-hiv-wirkung
ATE429448T1 (de)	2009-05-15	Peptidzusammensetzung als immunogen zur allergiebehandlung.
ZA200207992B (en)	2003-07-02	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid for induction of an immune response to amyloid and amyloid deposits.
ATE557041T1 (de)	2012-05-15	Peptid-vakzinen gegen streptokokken der gruppe a
HUP0102900A2 (hu)	2002-01-28	Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagok
NL300013I2 (nl)	2001-04-02	Nieuwe proteinen me TNF-remmende werking en hun bereiding.
PT1290013E (pt)	2006-06-30	Derivados dos peptidos apo-ai/aii
CY1108570T1 (el)	2014-04-09	Gd3-μιμητικα πεπτιδια
ATE508138T1 (de)	2011-05-15	N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
BR0309491A (pt)	2005-02-15	Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
ATE474589T1 (de)	2010-08-15	Angiogene peptide und ihre verwendungen
SE9002684D0 (sv)	1990-08-17	New peptides and their use
ES2176334T3 (es)	2002-12-01	El uso de gabapentin en el tratamiento de la ansiedad y el panico.
MXPA02012664A (es)	2004-05-14	Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
EA200100314A1 (ru)	2001-10-22	Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
WO1994004565A3 (fr)	1994-06-09	Vaccin vnpi
WO2001074847A3 (fr)	2002-03-21	Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer
AR009840A1 (es)	2000-05-03	Preparado vacunal para la inmunocastracion revesible de mamiferos
ECSP003720A (es)	2001-05-23	Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
SE0002738D0 (sv)	2000-07-19	Electric actuator